{
  "abstract": "Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide, underscoring the need for effective immunotherapeutic strategies. Here, we generated monoclonal antibodies against zona pellucida glycoprotein 3 (ZP3), developed ZP3-targeting chimeric antigen receptor macrophages (CAR-M), and evaluated their therapeutic potential in HCC.\n\nMethods: The recombinant extracellular domain of human ZP3 was expressed in HEK293F cells and used to immunize mice. CD138⁺ plasma cells were enriched and subjected to antigen-specific single-cell screening. Paired immunoglobulin variable-region sequences were recovered by nested polymerase chain reaction, followed by antibody cloning, expression, and purification. An anti-ZP3 single-chain variable fragment was incorporated into a lentiviral CAR construct and expressed in THP-1 cells, which were subsequently differentiated into macrophage-like cells. The phagocytic activity, cytotoxicity, polarization phenotype, cytokine secretion, in vivo antitumor efficacy, biodistribution, and preliminary safety of ZP3-targeting CAR-M were evaluated in HCC cell-based assays and Huh7 xenograft models.\n\nResults: Highly purified anti-ZP3 monoclonal antibodies were generated and shown to recognize membrane-associated ZP3 on Huh7 cells. Anti-ZP3 antibody treatment significantly suppressed tumor growth in peripheral blood mononuclear cell-reconstituted NOD-Scid mice. ZP3-targeting CAR-M exhibited efficient CAR expression and specific ZP3 binding, together with enhanced phagocytosis and cytotoxicity against HCC cells compared with control macrophages. Antigen engagement promoted an M1-like phenotype, characterized by increased CD80 and CD86 expression, reduced CD163 and CD206 expression, and enhanced secretion of IL-6, IL-1β, TNF-α, and IFN-γ. In Huh7 xenograft-bearing mice, systemic administration of CAR-M significantly delayed tumor progression. After treatment, body weight remained stable, most serum biochemical parameters responded basically normal, and major organs exhibited favorable tolerability.\n\nConclusions: ZP3 is a promising immunotherapeutic target in HCC. ZP3-directed antibodies and CAR-M demonstrated preclinical antitumor activity, supporting further development of ZP3-targeted immunotherapies.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13062-026-00941-x.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China",
    "Key Laboratory of Environmental Oncology of Gansu Province, Lanzhou, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Caihao Qu"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Wenzhang Wu"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yujie Wei"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Xin Yan"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Daijun Wang"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Yumin Li"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0pwj9yay3fyw4.bib",
  "cited_by": 0,
  "doi": "10.1186/s13062-026-00941-x",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757223/",
  "id": "0pwj9yay3fyw4",
  "issns": [
    "1745-6150"
  ],
  "landing_url": "https://doi.org/10.1186/s13062-026-00941-x",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7203621533",
  "pdf_url": null,
  "pmcid": "PMC13757223",
  "pmid": "43021384",
  "published": "2026-08-17",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/0pwj9yay3fyw4.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:22:57Z",
      "native_id": "PMC13757223",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s13062-026-00941-x"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Targeting ZP3 with chimeric antigen receptor macrophages: a novel immunotherapeutic strategy for hepatocellular carcinoma",
  "title_text": "Targeting ZP3 with chimeric antigen receptor macrophages: a novel immunotherapeutic strategy for hepatocellular carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:22:57Z",
  "url": "https://research.draconitic.com/paper/0pwj9yay3fyw4",
  "venue": "Biology Direct",
  "versions": []
}